Jacob Grønnegaard of FujiFilm Diosynth Biotechnologies discussed how the company’s unique cloning processes dramatically reduce project execution time, effort and expense at Emerson Exchange Immerse event. The result is intended to be one of the top medicine production facilities in the country. Hopefully, it won’t have to ramp up production for a virus vaccine to combat a worldwide pandemic, but if the time ever comes again, it will be scalable and ready.
Latest News
Calvin Butler to Join Emerson’s Board of Directors
Emerson today announced the appointment of Calvin Butler to its Board of Directors, effective August 1, 2024.
Emerson Reports Second Quarter 2024 Results; Updates 2024 Outlook
Emerson today reported results for the first quarter ended March 31, 2024.
Emerson’s New Flexible Control Package Helps OEMs and Small, Manufacturing Operations Develop...
The DeltaV Flex System provides scalable, subscription-based automation to reduce up-front cost and engineering complexity
